Jeffrey Humphrey's most recent trade in Lantheus Holdings Inc was a trade of 16,188 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 17, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Lantheus Holdings Inc | Jeffrey S. Humphrey | Chief Medical Officer | 17 Jun 2024 | 16,188 | 16,188 | - | - | Stock Option (right to buy) | ||
Lantheus Holdings Inc | Jeffrey S. Humphrey | Chief Medical Officer | 17 Jun 2024 | 9,076 | 9,076 (0%) | 0% | 82.6 | 749,950 | Common Stock | |
Cyteir Therapeutics Inc | Jeffrey Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 14,150 | 14,150 | - | - | Stock Option (Right to Buy) | |
Cyteir Therapeutics Inc | Jeffrey Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 2,358 | 2,358 | - | - | Stock Option (Right to Buy) | |
Cyteir Therapeutics Inc | Jeffrey Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2021 | 28,300 | 28,300 | - | - | Stock Option (Right to Buy) |